Kim BG, et al. - A retrospective observational analysis of data was performed from 894 consecutive, adult patients with chronic hepatitis B (CHB) undergoing entecavir (ETV) treatment at a tertiary referral hospital in Ulsan, Korea from January 1, 2007 through April 31, 2017 to compare the incidence of hepatocellular carcinoma (HCC) within and beyond the first 5 years of ETV in treatment-naïve Korean patients with CHB. In Korean CHB patients, the incidence rate of HCC might not change significantly before and after 5 years of ETV therapy. Results of this study suggested that the risk of HCC in Asian CHB patients might remain in the long-term.